BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22921738)

  • 1. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
    Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
    Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
    Junco JA; Peschke P; Zuna I; Ehemann V; Fuentes F; Bover E; Pimentel E; Basulto R; Reyes O; Calzada L; Castro MD; Arteaga N; López Y; Garay H; Hernández H; Bringas R; Guillén GE
    Vaccine; 2007 Dec; 25(50):8460-8. PubMed ID: 18022737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of different peptide combinations to increase the immunogenicity of the Gonadotrophin Releasing Hormone Vaccine for prostate cancer treatment.
    Aguilar FF; Barranco JJ; Aguilera LC; Fuentes EB; Serradelo Leal JA; López EH; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
    J Exp Ther Oncol; 2017 Nov; 12(2):87-94. PubMed ID: 29161775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
    Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
    J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
    Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
    Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
    Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
    Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
    Venier C; Guthmann MD; Fernández LE; Fainboim L
    Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.
    Junco JA; Basalto R; Fuentes F; Bover E; Reyes O; Pimentel E; Calzada L; Castro MD; Arteaga N; López Y; Hernández H; Bringas R; Garay H; Peschke P; Bertot J; Guillén G
    Adv Exp Med Biol; 2008; 617():581-7. PubMed ID: 18497085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.
    Ren J; Yang L; Xu H; Zhang Y; Wan M; Liu G; Zhao L; Wang L; Yu Y
    Vaccine; 2011 Oct; 29(45):7960-5. PubMed ID: 21872635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).
    Estevez F; Carr A; Solorzano L; Valiente O; Mesa C; Barroso O; Sierra GV; Fernandez LE
    Vaccine; 1999 Aug; 18(1-2):190-7. PubMed ID: 10501249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.
    Triozzi PL; Bolger GB; Neidhart J; Rinehart JJ; Saleh M; Allen KO; Sellers S; Waddell MJ
    Prostate; 2005 Dec; 65(4):316-21. PubMed ID: 16015596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions.
    Oliver L; Fernández A; Raymond J; López-Requena A; Fernández LE; Mesa C
    Vaccine; 2012 Apr; 30(19):2963-72. PubMed ID: 22391399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
    Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
    Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active component of a GnRH based vaccine binds to natural GnRH receptors in Dunning R3327-G cell line and human prostate carcinoma vesicles.
    Bover Fuentes E; Fuentes Aguilar F; Junco Barranco J; Zaldivar Merino I; Arteaga Moré N; Calzada Aguilera L; López Sáez Y; Pimentel Vázquez E; Basulto Baker R
    J Exp Ther Oncol; 2007; 6(4):279-84. PubMed ID: 18038761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.
    Valdes-Zayas A; Gonzalez Z; Mulens V; Vega AM; Perez K; Lorenzo-Luaces P; Rubio MC; Estevez A; Curbelo I; Fernandez LE; Crombet T; Mazorra Z
    J Immunother; 2017 Oct; 40(8):289-301. PubMed ID: 28604556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates.
    Morera Y; Bequet-Romero M; Ayala M; Velazco JC; Pérez PP; Alba JS; Ancizar J; Rodríguez M; Cosme K; Gavilondo JV
    Vaccine; 2010 Apr; 28(19):3453-61. PubMed ID: 20197134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.
    Barranco JA; Millar RP; Fuentes F; Bover E; Pimentel E; Basulto R; Calzada L; Morán R; Rodríguez A; Garay H; Reyes O; Castro MD; Bringas R; Arteaga N; Toudurí H; Rabassa M; Fernández Y; Serradelo A; Hernández E; Guillén GE
    Oncol Lett; 2016 Aug; 12(2):963-970. PubMed ID: 27446378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection.
    Jang SI; Lillehoj HS; Lee SH; Lee KW; Park MS; Bauchan GR; Lillehoj EP; Bertrand F; Dupuis L; Deville S
    Vet Parasitol; 2010 Sep; 172(3-4):221-8. PubMed ID: 20541870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.
    Simms MS; Scholfield DP; Jacobs E; Michaeli D; Broome P; Humphreys JE; Bishop MC
    Br J Cancer; 2000 Aug; 83(4):443-6. PubMed ID: 10945488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.